Business Context and Reporting Period
Trevi Therapeutics, Inc. (TRVI) filed a Form 8-K on June 2, 2025, reporting a corporate action regarding its capital raising activities. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not report standard periodic financial metrics such as revenue, profit, or operating cash flow. However, it discloses specific data related to an "at-the-market" (ATM) offering program:
- Shares Issued (ATM Program): 4,498,065 shares of Common Stock issued and sold as of March 31, 2025.
- Gross Proceeds: Approximately $14.6 million.
- Commissions and Fees: Approximately $0.5 million.
- Recent Activity: No shares were issued or sold under the Sales Agreement subsequent to March 31, 2025.
Material Changes
On June 2, 2025, the Company notified Leerink Partners LLC of the termination of the prospectus dated August 15, 2023, associated with their Sales Agreement. Consequently, the Company will not make any further sales of Common Stock under this agreement until a new prospectus is filed. The Sales Agreement itself remains in full force and effect.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the immediate cessation of stock sales under the current prospectus. The primary contingency noted is the requirement to file a new prospectus to resume sales under the existing Sales Agreement.
Investor Verification Checklist
- Verify the status of the new prospectus filing required to resume the ATM offering.
- Confirm the current cash balance and runway given the halt in ATM sales since March 31, 2025.
- Review the terms of the Sales Agreement to understand the conditions under which it remains in effect despite the prospectus termination.
- Check for any subsequent filings regarding the resumption of the offering program.